eFfector to collaborate with Northwestern University Hematology, Oncology

eFFECTOR Therapeutics announced the initiation of dosing in an investigator-initiated Phase 1 dose escalation trial evaluating tomivosertib in patients with relapsed/refractory Acute Myeloid Leukemia. The trial will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and chaired by Shira Dinner, M.D., Associate Professor of Medicine. Leonidas Platanias, M.D., Ph.D., Director, Robert H. Lurie Comprehensive Cancer Center and Professor of Medicine and Biochemistry and Molecular Genetics, and Jessica Altman, M.D., Professor of Medicine will serve as Co-Chairs of the trial. Tomivosertib is an inhibitor of mitogen-activator protein kinase interacting kinase 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E. Doug Warner, M.D., chief medical officer of eFFECTOR Therapeutics added: “We are excited to collaborate with the Northwestern team to further explore tomivosertib in hematologic settings as eFFECTOR continues to evaluate tomivosertib’s potential for treatment of solid tumors in non-small cell lung cancer.”